Olodaterol/tiotropium bromide

Drug Profile

Olodaterol/tiotropium bromide

Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva Respimat

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Jun 2017 Boehringer Ingelheim completes a phase I trial for Chronic obstructive pulmonary disease in China (Inhalation) (NCT02969317)
  • 01 Jun 2017 Nippon Boehringer Ingelheim initiates a clinical trial in Chronic obstructive pulmonary disease in Japan (UMIN000027190)
  • 17 Apr 2017 Boehringer Ingelheim completes a phase III trial for Chronic obstructive pulmonary disease in Japan (NCT02629965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top